{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:17:42Z","timestamp":1783937862284,"version":"3.55.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl-2 inhibitors, such as venetoclax. Overall survival (OS) and progression-free survival (PFS) of CLL patients are significantly improved with the use of these therapies. Adverse effects (AEs) that can occur during treatment and the presence of pre-existing comorbidities in patients can influence subsequent treatment outcomes and, consequently, OS and PFS. Managing these AEs, including cardiologic toxicity and infections (including fungal infections), as well as treating cardiovascular and other comorbidities, can be challenging due to potential drug interactions with the medications used for the management of AEs and comorbidities. Therefore, this review examined the key challenges associated with the concomitant use of novel CLL therapies and medications for managing comorbidities and AEs. This review aims to enhance and facilitate the management of patients with CLL.<\/jats:p>","DOI":"10.3389\/fphar.2024.1517972","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:50:25Z","timestamp":1735887025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges"],"prefix":"10.3389","volume":"15","author":[{"given":"Sofija","family":"Kozarac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Ivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Tomic Vujovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora","family":"Arsenovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Suvajdzic-Vukovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrija","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vidovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Todorovic-Balint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjana","family":"Mitrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Lekovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Djunic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Virijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Trivic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Micic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"B1","unstructured":"AbbVie\u2019s VENCLYXTO\u00ae\/VENCLEXTA\u00ae (venetoclax) continues to show sustained progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients\n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","article-title":"Effect of azithromycin on venetoclax pharmacokinetics in healthy volunteers: implications for dosing venetoclax with P-gp inhibitors","volume":"35","author":"Agarwal","year":"2018","journal-title":"Adv. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2024024631","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","author":"Al-Sawaf","year":"2024","journal-title":"Blood J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/cancers16050980","article-title":"Venetoclax initiation in chronic lymphocytic leukemia: international insights and innovative approaches for optimal patient care","volume":"16","author":"Anderson","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40959-017-0021-y","article-title":"Management of atrial fibrillation in patients taking targeted cancer therapies","volume":"3","author":"Asnani","year":"2017","journal-title":"Cardiooncology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1200\/edbk_279099","article-title":"Current perspectives on therapy for chronic lymphocytic leukemia","author":"Awan","year":"","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1161\/CIRCULATIONAHA.120.052047","article-title":"Cardio-oncology: a win-win situation: how solving the mystery of an ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms","volume":"142","author":"Awan","year":"","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/ijms22073304","article-title":"The PI3K\u03b4 inhibitor idelalisib diminishes platelet function and shows antithrombotic potential","volume":"22","author":"Barrachina","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00280-020-04179-w","article-title":"Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach","volume":"87","author":"Bhatnagar","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/leu.2014.12","article-title":"B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies","volume":"28","author":"Bojarczuk","year":"2014","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","article-title":"Targeting BTK in CLL: beyond ibrutinib","volume":"14","author":"Bond","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1080\/17425255.2016.1239717","article-title":"Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses","volume":"12","author":"Bose","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1016\/s2152-2650(22)01324-6","article-title":"CLL-115 first interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"22","author":"Brown","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3324\/haematol.2022.281402","article-title":"Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib","volume":"108","author":"Bye","year":"2022","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic Leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1080\/10428194.2018.1460474","article-title":"A drug-drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"59","author":"de Jong","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv."},{"key":"B30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling","volume":"100","author":"de Zwart","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/CAD.0000000000001541","article-title":"Venetoclax dose adjustment due to drug-drug interactions: a case report and literature review","volume":"35","author":"Fan","year":"2024","journal-title":"Anticancer Drugs"},{"key":"B37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s00280-020-04137-6","article-title":"Drug interactions with Bruton\u2019s tyrosine kinase inhibitors: clinical implications and management","volume":"86","author":"Fancher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1200\/JCO.23.02738","article-title":"Chronic lymphocytic leukemia: time to care for the survivors","volume":"42","author":"Fedele","year":"2024","journal-title":"JCO"},{"key":"B39","doi-asserted-by":"publisher","first-page":"oyae229","DOI":"10.1093\/oncolo\/oyae229","article-title":"Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy","author":"Fernandez Turizo","year":"2024","journal-title":"Oncologist"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1080\/10428194.2016.1251592","article-title":"Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) in routine clinical Practice","volume":"58","author":"Finnes","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1080\/10428194.2020.1775215","article-title":"Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"61","author":"Frei","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative prediction of the effect of CYP3A inhibitors and inducers on venetoclax pharmacokinetics using a physiologically based pharmacokinetic model","volume":"57","author":"Freise","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.3390\/cancers16112011","article-title":"Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed","volume":"16","author":"Fresa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","article-title":"Importance of P-glycoprotein at blood\u2013tissue barriers","volume":"25","author":"Fromm","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.3390\/cancers16111996","article-title":"Chronic lymphocytic leukemia: management of adverse events in the era of targeted agents","volume":"16","author":"Galitzia","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin. Electrophysiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"key":"B51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1517\/14656566.2016.1135130","article-title":"Idelalisib for the treatment of non-Hodgkin lymphoma","volume":"17","author":"Gopal","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.34787","article-title":"Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity","volume":"129","author":"Gordon","year":"2023","journal-title":"Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ijcard.2021.10.011","article-title":"Cardiovascular complications associated with novel agents in the chronic lymphocytic leukemia armamentarium: a pharmacovigilance analysis","volume":"344","author":"Grewal","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2165\/00002512-200522060-00006","article-title":"Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: st John's wort, garlic oil, Panax ginseng and Ginkgo biloba","volume":"22","author":"Gurley","year":"2005","journal-title":"Drugs Aging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B58","volume-title":"Imbruvica","year":"2024"},{"key":"B59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1182\/blood-2023-182397","article-title":"Long-Term outcomes in chronic lymphocytic leukemia treated with ibrutinib: 10-year follow-up of a phase 2 study","volume":"142","author":"Itsara","year":"2023","journal-title":"Blood"},{"key":"B60","volume-title":"Venetoclax, the first available bcl-2 antagonist for chronic lymphocytic leukaemia","author":"Janssens","year":"2024"},{"key":"B61","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/17512433.2022.2106968","article-title":"Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Jiang","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/jcph.504","article-title":"The pharmacokinetics and safety of idelalisib in subjects with moderate or severe hepatic impairment","volume":"55","author":"Jin","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/jcph.495","article-title":"Clinical drug interaction profile of idelalisib in healthy subjects","volume":"55","author":"Jin","year":"","journal-title":"J. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","article-title":"The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register","volume":"30","author":"Johnell","year":"2007","journal-title":"Drug Saf."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-hodgkin\u2019s lymphoma patients: a pooled population pharmacokinetic analysis","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single\u2010agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.12997\/jla.2019.8.2.162","article-title":"Aspirin for primary prevention of cardiovascular disease","volume":"8","author":"Kim","year":"2019","journal-title":"J. Lipid Atheroscler."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell\u2013mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26677","article-title":"Management of front line chronic lymphocytic leukemia","volume":"97","author":"Kutsch","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"E255","DOI":"10.1002\/ajh.26558","article-title":"Cardiovascular disease in patients with chronic lymphocytic leukemia: a Swedish nationwide register study with matched comparators","volume":"97","author":"Larsson","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.3324\/haematol.2016.155978","article-title":"Effects of ibrutinib treatment on murine platelet function during inflammation and in primary hemostasis","volume":"102","author":"Lee","year":"2017","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"B74","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/03602530701690374","article-title":"Drugs as CYP3A probes, inducers, and inhibitors","volume":"39","author":"Liu","year":"2007","journal-title":"Drug Metab. Rev."},{"key":"B75","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.amepre.2020.10.025","article-title":"Aspirin use and misuse for the primary prevention of cardiovascular diseases","volume":"60","author":"Luepker","year":"2021","journal-title":"Am. J. Prev. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"key":"B77","doi-asserted-by":"publisher","first-page":"622862","DOI":"10.3389\/fphar.2020.622862","article-title":"Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database","volume":"11","author":"Magro","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e007955","DOI":"10.1161\/CIRCEP.121.007955","article-title":"Drug interactions affecting antiarrhythmic drug use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ejim.2014.10.001","article-title":"Understanding adverse drug reactions in older adults through drug-drug interactions","volume":"25","author":"Marengoni","year":"2014","journal-title":"Eur. J. Intern Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.3324\/haematol.2017.187070","article-title":"Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia","volume":"103","author":"Martinelli","year":"2018","journal-title":"Haematologica"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"100608","DOI":"10.1016\/j.jscai.2023.100608","article-title":"Bleeding risk with antiplatelets and bruton\u2019s tyrosine kinase inhibitors in patients with percutaneous coronary intervention","volume":"2","author":"Mendez-Ruiz","year":"2023","journal-title":"J. Soc. Cardiovasc Angiogr. Interv."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","article-title":"Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia","volume":"5","author":"Mulder","year":"2021","journal-title":"Hemasphere"},{"key":"B84","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/2040620715625966","article-title":"The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia","volume":"7","author":"Nair","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"603569","DOI":"10.3389\/fimmu.2020.603569","article-title":"The role of alpha 2 macroglobulin in IgG-aggregation and chronic activation of the complement system in patients with chronic lymphocytic leukemia","volume":"11","author":"Naseraldeen","year":"2021","journal-title":"Front. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3324\/haematol.2018.193391","article-title":"Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI","volume":"103","author":"Nicolson","year":"2018","journal-title":"Haematologica"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/bph.14936","article-title":"Clinical relevance of St. John\u2019s wort drug interactions revisited","volume":"177","author":"Nicolussi","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B88","first-page":"4497","article-title":"The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response","volume":"63","author":"Orsini","year":"2003","journal-title":"Cancer Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1111\/bcp.14707","article-title":"Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP","volume":"87","author":"Ou","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ejpb.2019.07.014","article-title":"Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input","volume":"142","author":"Pepin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B92","unstructured":"Pharmacist\u2019s application to Practice: pirtobrutinib | HOPA\n          \n          \n          2023"},{"key":"B93","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/bloodadvances.2023011964","article-title":"Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs","volume":"8","author":"Prosty","year":"2023","journal-title":"Blood Adv."},{"key":"B94","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40262-015-0304-0","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of idelalisib","volume":"55","author":"Ramanathan","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11912-022-01261-9","article-title":"Managing the risk of infection in chronic lymphocytic leukemia in the era of new therapies","volume":"24","author":"Rivera","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"608625","DOI":"10.3389\/fimmu.2021.608625","article-title":"The PI3K\u2202-Selective inhibitor idelalisib induces T- and NK-cell dysfunction independently of B-cell malignancy-associated immunosuppression","volume":"12","author":"Rohrbacher","year":"2021","journal-title":"Front. Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMc1309710","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Rushworth","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1124\/dmd.114.060061","article-title":"Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men","volume":"43","author":"Scheers","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"B102","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/cpdd.1153","article-title":"Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables coadministration with proton-pump inhibitors","volume":"11","author":"Sharma","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"B108","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"","journal-title":"Lancet Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet Haematol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"B113","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ejh.13928","article-title":"High risk of infection in \u2018real-world\u2019 patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia\/lymphoma","volume":"110","author":"Tey","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","article-title":"Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/10428194.2017.1339874","article-title":"Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management","volume":"59","author":"Thorp","year":"2018","journal-title":"Leukemia & Lymphoma"},{"key":"B116","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN Guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3.2022","volume":"20","author":"Wierda","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"B118","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5334\/gh.1323","article-title":"Global prevalence of aspirin use for primary prevention of cardiovascular disease: a cross-sectional study of nationally representative, individual-level data","volume":"19","author":"Yoo","year":"2024","journal-title":"Glob. Heart"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1517972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:50:31Z","timestamp":1735887031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1517972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":118,"alternative-id":["10.3389\/fphar.2024.1517972"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1517972","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"article-number":"1517972"}}